39 reports of this reaction
1.6% of all CEFPROZIL reports
#17 most reported adverse reaction
OROPHARYNGEAL PAIN is the #17 most commonly reported adverse reaction for CEFPROZIL, manufactured by Ascend Laboratories, LLC. There are 39 FDA adverse event reports linking CEFPROZIL to OROPHARYNGEAL PAIN. This represents approximately 1.6% of all 2,368 adverse event reports for this drug.
Patients taking CEFPROZIL who experience oropharyngeal pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OROPHARYNGEAL PAIN is a less commonly reported adverse event for CEFPROZIL, but still significant enough to appear in the safety profile.
In addition to oropharyngeal pain, the following adverse reactions have been reported for CEFPROZIL:
The following drugs have also been linked to oropharyngeal pain in FDA adverse event reports:
OROPHARYNGEAL PAIN has been reported as an adverse event in 39 FDA reports for CEFPROZIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
OROPHARYNGEAL PAIN accounts for approximately 1.6% of all adverse event reports for CEFPROZIL, making it a notable side effect.
If you experience oropharyngeal pain while taking CEFPROZIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.